Zymeworks Inc. (ZYME)
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
Zymeworks NASDAQ: ZYME said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a commercial organization to its business.
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.03 per share a year ago.
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.
Theravance Stock Down 3% After Zymeworks Announces Buyout
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine, offering a differentiated risk-reward profile versus traditional biotech peers. ZYME's balance sheet is fortified with over $400 million in liquid assets, a $440 million milestone pipeline, and a $125 million share repurchase program, supporting operations beyond 2028. Zanidatamab's Priority Review for first-line HER2-positive GEA, with a PDUFA date of August 25, 2026, could trigger $265 million in near-term milestone payments and unlock substantial royalty streams.
Zymeworks Q1 Earnings Call Highlights
Zymeworks NASDAQ: ZYME reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across its antibody-drug conjugate pipeline and continued share repurchases.
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.3 per share a year ago.
